SIPULEUCEL-T PUBLICATIONS

• Higano CS, Schellhammer PF, Small EJ, et al. Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Cancer 2009; 115:3670–9.
• Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008;57(9):1381-1390. PMID 18297282
• Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ.
  Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (PROVENGE) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
  Cancer. 2006 Jul 1; 107(1):67-74
  PMID: 16736512
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.
  Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asympotomiatic hormone refractroy prostate cancer.
  J Clin Oncol. 2006 Jul 1; 24(19):3089-94
  PMID: 16809734
• Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S.
  Immunotherapy (APC8015, PROVENGE) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
  Prostate. 2004 Aug 1; 60(3):197-204
  PMID: 15176049
• Laus R, Yang D M, Ruegg C L, Shapero M H, Slagle P H, Small E, Burch P, and Valone F H.
  "Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience."
  Cancer Research Therapy and Control. 2001 Nov; 1-10.
• Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S.
  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
  Clin Cancer Res. 2000 Jun; 6(6):2175-82
  PMID: 10873066
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH.
  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
  J Clin Oncol. 2000 Dec 1; 18(23):3894-3903
  PMID: 11099318

LAPULEUCEL-T PUBLICATIONS

• Peethambaram PP, Melisko ME, Rinn KJ, et al. A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu. Clin Cancer Res 2009; 15:5895-901.
• Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol. 2007;25(24):3680-3687. PMID: 17704416
• Diegel, ML, Chen, F, Laus, R, Graddis, TJ, & Vidovic, D "MHC class I-restricted presentation of protein antigens without prior intracellular processing," Scand J. Immunol., 58:1-8, 2003.
• Vidovic, D, Graddis, TJ, Stepan, LP, Zaller, DM & Laus, R "Specific stimulation of MHC transgenic mouse T cell hybridomas with xenogeneic APC," Human Immunol. 64:238-244, 2003
• Vidovic, D, Graddis, TJ, Chen, F, Slagle, PH, Diegel, ML, Stepan, L.P. & Laus, R. "Anti-tumor vaccination with HER-2 derived recombinant antigens," Int. J. Cancer 102:660-664, 2002
• Valone F, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R, "Dendritic Cell-Based Treatment of Cancer: Closing in on a Cellular Therapy," The Cancer Journal: 7, S53-S61, 2001.